The Oncology Institute, Inc.
NASDAQ:TOIMedical - Care Facilities
-$0.07 today
- Market cap
- $512.91M
- Beta
- 0.41
- P/E (TTM)
- -121.1
- EPS (TTM)
- -$0.04
Volume 1.21M
Average 1.74M
TOI Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
The Oncology Institute, Inc.NASDAQ: TOI
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt rises 19.2% from a year ago
Net debt stood at $74.58M at the end of Q1 FY2026, up 19.2% from a year earlier and up 6.4% from the prior quarter. Over 3 fiscal years it compounded at -9.4% a year.
Context
- Net debt amounted to 44.3% of total assets at the end of Q1 FY2026, up 6.2 pp from a year earlier.
- Net debt increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +19.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- 70.12M USD
- Year-over-year change
- -4.6%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 70.12M | -4.6% |
| FY2024 | 2024-12-31 | 73.48M | -14.7% |
| FY2023 | 2023-12-31 | 86.19M | -8.5% |
| FY2022 | 2022-12-31 | 94.17M | +182.5% |
| FY2021 | 2021-12-31 | (114.12M) | — |
Net Debt vs competitors
How TOI compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +19.2% is the 5th highest of 10, against a peer median of -3.6%.
- Net debt amounts to 44.3% of total assets for TOI, versus a peer median of 18.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
AUNAAuna S.A. | Mar 2026 | PEN 3.41B PEN | -3.6% | +0.2% | 44.3% |
| Mar 2026 | $1.54B USD | +141.5% | +1.2% | 58.5% | |
| Mar 2026 | $115.11M USD | +84.7% | +70.3% | 52.2% | |
| Mar 2026 | $92.03M USD | +131.5% | — | 18.3% | |
| Mar 2026 | $74.58M USD | +19.2% | -9.4% | 44.3% | |
| Mar 2026 | $4.01M USD | -92.8% | -59.5% | 2.2% | |
CBLLCeriBell, Inc. | Mar 2026 | -$23.14M USD | +82.4% | — | 13.0% |
| Mar 2026 | -$50.97M USD | -123.7% | — | 9.7% | |
| Mar 2026 | -$103.54M USD | -33.8% | — | 23.0% | |
| Mar 2026 | -$106.59M USD | -10.3% | — | 7.1% | |
| Peer median (excluding TOI) | — | -3.6% | +0.7% | 18.3% | |
Competitors are the stored peer set for TOI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 114.3M | 14.01M | 33.49M | 49.67M | 33.57M |
| Short-term Investments | 0 | 59.8M | 49.37M | 0 | 0 |
| Net Receivables | 21.24M | 40.43M | 42.91M | 48.68M | 59.32M |
| Inventory | 6.44M | 9.26M | 13.68M | 10.04M | 16.88M |
| Other Current Assets | 875K | 0 | 0 | 4.03M | 2.99M |
| Total Current Assets | 154.06M | 130.42M | 143.49M | 112.42M | 112.75M |
| Property, Plant & Equipment (Net) | 4.19M | 33.04M | 40.05M | 37.67M | 33.06M |
| Goodwill | 26.63M | 21.42M | 7.23M | 7.23M | 7.23M |
| Intangible Assets | 18.25M | 17.96M | 17.9M | 14.81M | 11.02M |
| Long-term Investments | (371K) | 58.35M | 0 | 0 | 0 |
| Tax Assets | 371K | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 320K | 477K | 561K | 589K | 606K |
| Total Non-current Assets | 49.38M | 131.25M | 65.75M | 60.3M | 51.91M |
| Total Assets | 203.44M | 261.67M | 209.24M | 172.72M | 164.66M |
| Account Payables | 15.56M | 9.37M | 14.43M | 24.32M | 43.17M |
| Short-term Debt | 183K | 0 | 0 | 0 | 0 |
| Tax Payables | 132K | 255K | 0 | 0 | 0 |
| Deferred Revenue | 592K | 1.14M | 545K | 4.7M | 2.28M |
| Other Current Liabilities | 10.14M | 9.35M | 11.33M | 10.35M | 13.15M |
| Total Current Liabilities | 29.8M | 29.72M | 34.79M | 52.22M | 70.96M |
| Long-term Debt | 0 | 80.62M | 86.83M | 93.13M | 77.4M |
| Deferred Tax Liabilities | 371K | 108K | 32K | 32K | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 69.11M | 5.98M | 4.08M | 527K | 12.88M |
| Total Non-current Liabilities | 69.48M | 108.77M | 117.43M | 116.91M | 109.41M |
| Total Liabilities | 99.28M | 138.49M | 152.22M | 169.13M | 180.38M |
| Common Stock | 7K | 7K | 8K | 8K | 10K |
| Retained Earnings | (63.23M) | (63.08M) | (146.15M) | (210.81M) | (271.42M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 104.16M | 123.18M | 57.03M | 3.59M | (15.72M) |
| Total Debt | 183K | 108.18M | 119.68M | 123.15M | 103.69M |
| Net Debt | (114.12M) | 94.17M | 86.19M | 73.48M | 70.12M |
The Oncology Institute, Inc.
NASDAQ:TOI
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.